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ABSTRACT
Over the past decades, prognosis of patients with cancer 
has strongly improved and the number of cancer survivors 
is rapidly growing. Despite this success, cancer treatment 
is associated with development of serious cardiovascular 
diseases including left ventricular (LV) systolic dysfunction, 
heart failure, valvular disease, myocardial infarction, 
arrhythmias or pericardial diseases. Serial non- invasive 
cardiac imaging is an important tool to detect early signs 
of cardiotoxicity, to allow for timely intervention and 
provide optimal circumstances for long- term prognosis. 
Currently, echocardiographic imaging is the method of 
choice for the evaluation of myocardial function during 
and after cancer therapy. However, 2D echocardiography 
may fail to detect subtle changes in myocardial function, 
potentially resulting in a significant delay of therapeutic 
intervention to impede advanced cardiac disease states 
with more overt systolic dysfunction. Strain imaging is 
a promising method for early detection of myocardial 
dysfunction and may predict future changes in LV ejection 
fraction. The use of three- dimensional echocardiography 
may overcome the limitations of 2D echocardiography 
with more precise and reproducible measurements of 
LV performance. Cardiac MRI is the gold standard for 
volumetric assessment and can also be used to perform 
myocardial tissue characterisation. Visualisation of 
oedema and fibrosis may provide insights into the degree 
and disease course of cardiotoxicity and underlying 
pathophysiological mechanisms. There is growing body of 
literature regarding the promising role of these advanced 
imaging modalities in early detection of cardiotoxicity. 
With this overview paper, new insights and recent results 
in literature regarding echocardiographic and cardiac 
magnetic resonance imaging of cancer therapy- related 
cardiac dysfunction in post- cancer therapy adults will be 
highlighted.
INTRODUCTION
Over the past decades, prognosis of patients 
with cancer has strongly improved and 
the number of cancer survivors is rapidly 
growing.1 Despite this success, cancer treat-
ment is associated with increased risk of 
morbidity and mortality during long- term 
follow- up.2 Current anticancer protocols 
include anthracyclines, tyrosine kinase 
inhibitors and monoclonal antibody 
therapy, which can cause ventricular systolic 
dysfunction (cancer treatment- related 
cardiac dysfunction (CTRCD)) later in life. 
CTRCD may progress to heart failure over 
time.2 The incidence and degree of CTRCD 
depends on type of the used cancer drug, 
cumulative dose and (pre- )existing cardio-
vascular comorbidities.3
Currently, echocardiographic imaging is 
the method of choice for the evaluation of 
myocardial function during and after cancer 
therapy. Left ventricular (LV) ejection frac-
tion (EF) is frequently used as predictor for 
cardiac outcomes, but is not the optimal 
parameter for detection of subtle alter-
ations in systolic myocardial performance.4 
Compensatory mechanisms may mask subtle 
LV dysfunction and clinical manifestations 
of myocardial injury can therefore occur 
years after cancer therapy.4 Asymptomatic 
patients with CTRCD may remain unrec-
ognised by serial LVEF assessment, so early 
therapeutic intervention can be delayed until 
a later cardiac disease state. Early treatment 
with heart failure medication may improve 
recovery of myocardial dysfunction in a 
substantial part of patients.5
In recent years, the field of cardio- oncology 
has substantially evolved and the number of 
published studies is growing exponentially. 
Accordingly, the purpose of this overview 
paper is to provide a summary of the latest 
insights and recent results in literature about 
the current role of echocardiographic and 
cardiac magnetic resonance imaging (MRI) 
monitoring of CTRCD in adult patients with 
cancer and survivors.
Hence, a non- systematic literature search 
in PubMed and EMBASE was performed to 
extract original reports about imaging param-
eters for cardiac surveillance in patients with 
cancer treated with cardiotoxic treatment. 
A narrative synthesis of those reports with 
potential impact on clinical practice and 
future research is provided in the current 
manuscript. Imaging modalities as equilib-
rium radionuclide angiography (also known 
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The most widely used method for the evaluation of LV 
function in patients with cancer at risk for CTRCD is 
assessment of LVEF by two- dimensional (2D) echocardi-
ography.4 The European Society of Cardiology position 
paper from 2016 defined the lower limit of normal of 
LVEF as 50%, whereas the American Society of Echocardi-
ography (ASE)/European Association of Cardiovascular 
Imaging (EACVI) expert consensus from 2014 defined 
CTRCD as a decrease in LVEF exceeding 10% points, to 
a value <53%.2 4 However, LVEF measured by 2D echo-
cardiography is less suited to detect subtle changes in 
systolic function since the variability in LVEF measures 
can be approximately 10%.6 This may be caused by LV 
geometric assumptions and difficulties in visualising the 
apex. Abnormalities in regional wall displacement can 
also be difficult to detect with 2D echocardiography.4 In 
addition, LVEF is susceptible to volume loading condi-
tions which may vary significantly during chemotherapy.
Changes in LVEF ultimately occur when compensa-
tory mechanisms fail in the affected myocardium. Recent 
developments in echocardiographic techniques including 
myocardial strain by speckle tracking echocardiography 
(STE) and three- dimensional (3D) echocardiography 
offer possibilities for more accurate and subclinical 
detection of systolic dysfunction.6 7 Thavendiranathan et 
al demonstrated that during treatment of patients with 
breast cancer with stable cardiac function, estimations of 
LVEF by 3D echocardiography had temporal variability of 
approximately 6%.6
Myocardial deformation
STE quantifies myocardial deformation by tracking 
speckle displacement during the cardiac cycle. Strain 
is expressed as percentage, which corresponds with the 
amount of deformation in a region of interest (ie, short-
ening or lengthening) in respect to the initial length, 
often measured at the end of diastole. The most eval-
uated STE parameter is 2D global longitudinal strain 
(GLS), which is the average of the strain values in the 
longitudinal direction of all 17 segments according to 
the ASE/EACVI LV segmentation model.8 Recently, 3D 
strain measurements are emerging, for which, similar 
to 3D LVEF assessment, no multiple apical images are 
required.
In the last decade, landmark reports demonstrated the 
additive value of strain assessment after cardiotoxic treat-
ments.9–11 These results revealed that early decreases in 
deformation parameters during or after cancer therapy in 
adults allowed to predict subsequent LVEF deterioration. 
The ASE/EACVI Expert Consensus therefore strongly 
supports the use of GLS during follow- up, with a clinically 
significant deterioration of LV deformation supported by 
a relative percentage decrease of >15% when compared 
with baseline. Changes of <8% are considered normal 
as this concerns inter- variability and intra- variability of 
measurements.4 A recent prospective study in adults with 
lymphoma or leukaemia who were treated with a cumula-
tive anthracyclines dose up to 300 mg/m2, demonstrated 
that (2D) GLS >−17.45% at a cumulative anthracycline 
dose of >150 mg/m2 is an independent predictor of 
future CTRCD, defined as a decrease in the LVEF of 
>10% points to a value <53%.12 Pretreatment measure-
ments of GLS in this cohort were significantly lower in 
the CTRCD group than in the non- CTRCD group, which 
may suggest an increased baseline risk profile for cardio-
vascular disease. This finding is supported by the study of 
Ali et al; their results demonstrated that reduced baseline 
GLS was a strong predictor of cardiac events in patients 
with haematologic cancers. A GLS threshold of −17.5% 
before anthracycline therapy would have correctly identi-
fied 86% of the patients who develop a cardiac event after 
start of chemotherapy, defined as symptomatic heart 
failure or cardiac death.13
In addition, worse basal longitudinal strain after 
chemotherapy was—in contrast to worse GLS—associ-
ated with CTRCD in 61 anthracycline- treated patients. 
Since GLS is the average of all LV segments, it is possible 
to underestimate regional impairment, whereas basal 
longitudinal strain may be a more sensitive marker of 
CTRCD. However, further research is needed to assess its 
clinical relevance.14
Global circumferential strain (GCS) may also be 
predictive for the occurrence of CTRCD. In the study of 
Narayan et al, every 1% reduction in GCS compared with 
baseline circumferential strain was associated with an OR 
of 1.21 (95% CI 1.10 to 1.34) for developing CTRCD in 
women receiving breast cancer therapy (n=135), inde-
pendent of relevant co- variables such as age, history of 
cardiovascular risk factors, treatment regimen and time 
since start of treatment.15
A novel deformation parameter—area strain (AS)—
can be obtained with 3D STE. This parameter is calcu-
lated by combining the effects of GLS and GCS, so AS can 
be considered as parameter that integrates LV myocar-
dial deformation.16 In 67 patients with breast cancer, the 
mean of global AS (%) deteriorated significantly between 
baseline and after anthracycline therapy (−30.2±4.5 and 
−27.5±5.4, respectively).17
Right ventricular (RV) function
Assessment of RV function is considered increasingly 
important. A recent report in patients with cancer treated 
with cardiotoxic treatment demonstrated concomitant 
abnormalities in longitudinal strain of the free RV wall 
in 75% of cases (n=20) with LVEF drop >10% to <53% 
(6 months after initiation of chemotherapy).18 Conven-
tional RV functional parameters (ie, tricuspid annular 
plane systolic excursion) were within normal ranges, 
suggesting that this novel RV strain parameter could be 
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results should be affirmed in larger studies with a longer 
follow- up period.
LV mass and diastolic function
Lipshultz et al demonstrated that both LV thickness–
dimension ratio and LV mass were significantly reduced 
in anthracycline- treated childhood cancer survivors.19 
However, in adults, early evidence of remodelling may 
be reversible as Narayan et al demonstrated increased LV 
mass 1 year after anthracycline therapy which normalised 
in the years thereafter.20
Reduced LV diastolic function may also occur as part of 
CTRCD, as reflected by abnormal mitral E velocity, E/A 
ratio, isovolumic relaxation time or tissue Doppler veloci-
ties.4 Anthracycline dose, age at treatment and BMI have 
been reported as risk factors of diastolic dysfunction.21 22 
However, the prognostic value of LV diastolic impairment 
to predict CTRCD is doubtful because of inconsistent 
results regarding its ability to predict subsequent occur-
rence of systolic dysfunction.20 22 23
CARDIAC MAGNETIC RESONANCE IMAGING
Cardiac MRI is a non‐invasive imaging technique that 
allows for accurate and reproducible assessment of 
biventricular volumes, mass and function with negligible 
inter- observer and intra- observer variability.24 25 Besides 
anatomical and functional assessment, cardiac MRI allows 
for myocardial tissue characterisation by use of late gado-
linium enhancement (LGE) and quantitative mapping 
techniques (T1 and T2 mapping).26
LV function
For the surveillance of oncology patients, cardiac MRI 
-derived LVEF is considered as reference standard for LV 
systolic performance.2 24 To detect small changes in LVEF, 
assessment with cardiac MRI is well- suited in patients with 
good health and non- cancer heart failure with a temporal 
variability of 2.4%–7.3%.25
Recent reports have demonstrated that also cardiac 
MRI- derived LV strain allows detecting subclinical LV 
dysfunction, during and after potentially cardiotoxic 
cancer therapy.27 28 During follow- up of 41 trastuzumab- 
treated patients, significant reductions in GLS and GCS 
were observed at 6 and 12 months when compared with 
baseline. These alterations were related with concurrent 
decreases in LVEF.29 To enhance the potential transition 
from echocardiographic LV- measurements to cardiac 
MRI, Jolly et al proposed an automated measurement 
of GCS from CMR cine images in patients treated with 
chemotherapy. They demonstrated that GCS can be 
obtained in ~7 min from routine cine LV short axis images 
in 98.6% of the patients (n=72) and the observed wors-
ening in GCS correlated with LVEF decline on cardiac 
MRI.28
LV volume
Alterations in LV dimensions should always be consid-
ered when evaluating changes in LVEF, since a decline in 
LVEF can be the result of an increased left ventricular end 
systolic volume (LVESV) or reduction of left ventricular 
end diastolic volume (LVEDV). CTRCD is associated 
with an increased LVESV (with a preserved LVEDV)—as 
a reflection of reduced myocardial contractility—while 
reduced LVEDV can, for example, be observed in patients 
who are volume- depleted during chemotherapy.26 Two 
recent studies demonstrated that CTRCD, based on 
drop in strain or LVEF measurements, was related to an 
isolated decline in LVEDV in 16%–19% of patients, indi-
cating that in part of the patients with decreased systolic 
function, this may be the result of volume depletion.27 30 
Also important, an increased LVESV due to CTRCD can 
(partly) be compensated by increased LVEDV as part 
of cardiac remodelling, to preserve LVEF and cardiac 
output. Evaluation of LV dimensions by cardiac MRI 
should therefore be an integral part of cardiac evalua-
tion, in addition to systolic function parameters.
LV mass can also be measured by cardiac MRI with 
higher accuracy and reproducibility compared with 
echocardiography.31 Neilan et al demonstrated an inverse 
correlation between decrease in LV mass after chemo-
therapy and anthracycline dose, and that LV mass index 
<57 g/m2 was a predictor of adverse cardiac events.32 
Also, Jordan et al showed a significant association between 
worsening of heart failure symptoms and declines in LV 
mass after accounting for both changes in LVEF and 
changes in body weight.33 This may suggest that remod-
elling of the LV structure precedes myocardial function 
impairment. Evaluation and quantification of LV mass by 
cardiac MRI is therefore advised in (suspected) CTRCD.
RV function
In addition, cardiac MRI can be used to study RV perfor-
mance. Several studies have demonstrated significant 
changes in RV systolic function, structure and dimensions 
during and after systemic cancer treatment.34–36 Recently, 
a prospective study of patients with breast cancer (n=41) 
demonstrated a significant decrease in RVEF from 58.3% 
(95% CI 57.1% to 59.5%) to 53.9% (95% CI 52.5% to 
55.4%, p<0.001) and increases in right ventricular end 
diastolic volume (RVEDV) and right ventricular end 
systolic volume (RVESV) at 6 months after initiation of 
trastuzumab, however, these measurements reversed after 
completion of therapy. RVEF and LVEF changed in a 
similar pattern, but the relationship was non- significant.36 
Further studies are required to explore the prognostic 
value of RV evaluation in oncology patients.
Myocardial tissue characterisation
Imaging by cardiac MRI enables visualisation and 
characterisation of myocardial tissue.37 38 Formation 
of fibrosis due to collagen breakdown is one of the 
proposed molecular mechanisms of anthracycline- 
associated myocardial remodelling.39 There are several 
cardiac MRI techniques to detect fibrosis, including 
LGE imaging and mapping parameters. Visualisation 
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differences in signal intensity.37 Since interstitial 
fibrosis as late effect of cancer treatment is likely to be 
diffuse,24 LGE seems less suitable for the surveillance 
of CTRCD,35–37 40–42 except for the detection of toxic 
myocarditis or previous cardiac events such as myocar-
dial infarcts.40 To detect diffuse myocardial diseases, 
specific mapping parameters (T1, T2, T2*) and extra-
cellular volume (ECV) are important cardiac MRI 
techniques that depend on molecular environment in 
a myocardial voxel and quantify intracellular changes 
of the cardiomyocyte and extracellular changes in the 
myocardial interstitium.37 38
Molecular environment changes may be caused by 
oedema, interstitial fibrosis or other more rare causes 
(ie, cardiac amyloidosis). Increases in T1 and T2 
values reflect myocardial fibrosis and oedema, respec-
tively. As a result of these processes, the extracellular 
matrix can expand, expressed by an increased ECV.38 
In a recent pig study, cardiac MRI evaluation over a 
period of 16 weeks after anthracycline administration 
showed that the acute phase of myocardial injury was 
characterised by prolongation of T2 relaxation time. 
Significant changes in LVEF, ECV and T1 mapping 
occurred only weeks later. T2 relaxation time prolon-
gation in the acute phase was correlated with oedema 
within the cardiomyocyte. Withholding anthracycline 
administration at the time of occurrence of T2 abnor-
malities prevented development of subsequent LV 
systolic dysfunction.43
Reports of myocardial mapping in oncology patients 
are generally mixed in results; myocardial oedema 
after receipt of anthracycline and/or trastuzumab was 
demonstrated in almost half of the patients at 1 or 
4 months after initiation of therapy, but LV dysfunc-
tion could not be predicted.34 In a 5- year follow- up 
study, both LV function and T1 mapping values were 
within the normal limits.42 Muehlberg et al described 
different findings with regard to cardiac MRI values 
in sarcoma patients shortly after anthracycline- based 
chemotherapy. Within 48 hours after chemotherapy 
initiation, native T1 decreased significantly in patients 
who developed CTRCD (LVEF drop >10% points) at 
the end of the chemotherapy. T1 values normalised 
in all CTRCD cases after treatment completion and 
myocardial T2 mapping values did not significantly 
change during chemotherapy.41 The authors suggest 
that development of CTRCD may consist of different 
phases and therefore the interpretation of cardiac 
MRI results after anthracycline therapy may be 
adapted to the timing of assessment.41
In addition, a recent study by Altaha et al demon-
strated greater temporal differences in T1, T2 and 
ECV in patients with HER2- positive breast cancer with 
CTRCD (n=10), defined as >10% reduction in LVEF 
to <55% or >15% relative reduction in GLS, compared 
with patients without CTRCD and healthy participants. 
However, the results in patients with CTRCD overlap 
with variability in healthy participants, emphasising 
the difficulty of interpreting mapping measurements 
in individual patients.44
A landmark study of Jordan et al compared pretreat-
ment (n=37) and post- treatment patients with cancer 
(n=37) with cancer- free controls (n=236), demon-
strating elevated ECV 3 years after anthracycline treat-
ment.45 It is important to stress that cardiovascular 
risk factors, often present in patients with cancer,46 
are associated with elevations in ECV. Increase in 
ECV in this study was independent of cardiovascular 
risk factors, which corroborates the hypothesis that 
myocardial fibrosis develops after cancer treatment.45 
Accordingly, pretreatment cardiac MRI is crucial 
to interpret the myocardial tissue characteristics 
reflected by cardiac MRI. A more recent study indi-
cated that interstitial myocardial fibrosis—reflected 
by elevated ECV—may arise within 3 months after 
initiation of cardiotoxic chemotherapy (71% received 
anthracyclines).47 De Souza et al also suggested that 
decreased cardiomyocyte size may contribute to an 
increase in ECV.48
The online supplemental contains E- figures that 
demonstrate the different cardiac MRI parameters in a 
case with CTRCD.
CLINICAL PRACTICE
Currently, cardiac follow- up of patients with increased 
risk for CTRCD is based on expert consensus. Teske et 
al provided an overview about the available evidence 
and clinical practice in our institution which will be 
referred to in the following section.49 Typically, the 
surveillance of adult patients with cancer who will 
receive cardiotoxic agents starts before initiation of 
cancer therapy and ends up to 1 year after last chemo-
therapy dose. The frequency of follow- up is based on 
the individual risk profile for CTRCD, which incorpo-
rates parameters such as type and dosage of chemo-
therapy, age at time of chemotherapy and presence of 
cardiovascular risk factors.49
The results of the recently published studies show 
that CTRCD can affect multiple parts of the myocar-
dium and therefore reinforce the recommendation of 
a comprehensive and systematic echocardiographic 
assessment of at least LV systolic and diastolic func-
tion, LV strain and RV function.4 It is important to 
use the same imaging modality over time to enhance 
adequate interpretation of serial measurements and 
identification of individual CTRCD.4 Since the accu-
racy in LV measurements by 3D echocardiography 
has expanded in clinical care, this modality is recom-
mended for serial LVEF measurements in patients 
with cancer.4 Regarding myocardial strain, a clear 
superiority of 3D STE over 2D STE has not been 
reported yet, although results of 3D- derived strain are 
promising.16 17
The use of cardiac MRI is recommended as a comple-
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and when evaluation of other underlying causes of 
LV dysfunction is indicated.2 4 Despite the superior 
qualities of cardiac MRI, this modality is (in the Neth-
erlands) approximately three times more expensive 
and less available than echocardiography. In our own 
institution, CMR is routinely used in case of clin-
ical CTRCD on transthoracic echocardiography and 
considered in case of subclinical CTRCD.49 Further-
more, cardiac MRI provides additional diagnostic and 
prognostic information in patients with known cardiac 
disease, that is, previous myocardial infarction.
Heart failure medication is only initiated in adult 
patients with evidence of CTRCD, defined as LVEF 
>10% decline to LVEF <53% or GLS decline of 15% and 
NYHA ≥II/IV or LVEF <45% on echocardiography.49
FUTURE PERSPECTIVES
In the future, strain measurements may replace LVEF 
for early detection of CTRCD and its incremental 
clinical value needs to be further explored. An 
important question remains what the consequences 
are for an asymptomatic patient with reduced strain 
and preserved LVEF. The SUCCOUR (Strain sUrveil-
lance of Chemotherapy for improving Cardiovascular 
Outcomes) trial is the first (ongoing) randomised 
controlled trial in anthracycline- treated patients with 
cancer at risk of heart failure which compares the 
effect of GLS- guided versus LVEF- guided manage-
ment on 3D LVEF 3 years after diagnosis.50
Parameters as RV function, LV dimensions and 
mass, regional function as expressed by basal longi-
tudinal strain, circumferential strain, AS and diastolic 
measures have shown promising results to suggest that 
subclinical myocardial changes may precede global 
LV dysfunction, but it is too early to incorporate these 
in decision making and warrant therapeutic interven-
tion. Other novel technical parameters (eg, torsion, 
Tei index) are of potential interest, yet their incre-
mental value for clinical purposes has to be explored.
In addition, more research is needed on diagnostic 
and risk prediction models that combine echocar-
diographic measures with other potential predictors 
such as genetics, cardiovascular risk factors and blood 
biomarkers to improve and individualise cardiac 
surveillance and treatment.
Myocardial tissue characterisation by cardiac MRI 
offers the opportunity to improve follow- up of the 
myocardium over time and, especially in light of the 
potential introduction of anti- fibrosis medication, 
may provide important clinical information. There 
are only few high- quality studies that evaluated early 
(within 3 months after treatment) effects of cancer 
treatment, so more evidence is needed to elucidate 
its prognostic value. In the future, diffusion- weighted 
cardiac MRI images will also be available for the evalu-
ation of the myocardium, which enables evaluation of 
myocyte necrosis during the acute stage and has the 
potential to become a new biomarker.
CONCLUSION
Imaging techniques that allow for detection of early 
changes in myocardial function are crucial in the 
follow- up of cardiovascular diseases after cardiotoxic 
cancer treatment as exemplified in figure 1. Advanced 
imaging techniques may be of additive value due to 
better reproducibility and, even more important, the 
Figure 1 Detection of CTRCD using non- invasive imaging. The progress of CTRCD can be subdivided into different phases. 
Multiple non- invasive modalities play an important role in order to detect CTRCD as early as possible. Interstitial myocardial 
changes including oedema and fibrosis shortly after start of chemotherapy can be reflected by tissue characterisation with 
cardiac MRI. Thereafter, changes in myocardial function may occur. Myocardial strain is an important parameter of early to 
intermediate cardiac impairment which can be measured by echocardiography and MRI. On the long term, months to years 
after start of chemotherapy treatment, asymptomatic left ventricle systolic dysfunction may progress to heart failure so follow- 
up based on left ventricular ejection fraction is recommended. CTRCD, cancer treatment- related cardiac dysfunction; DWI, 
diffusion- weighted imaging; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; MRI, magnetic resonance 





















6 de Baat EC, et al. Open Heart 2021;8:e001506. doi:10.1136/openhrt-2020-001506
introduction of novel parameters appears to improve 
our pathophysiological understanding of CTRCD and 
predict subsequent cardiac outcome. Tissue charac-
terisation by cardiac MRI and early signs of myocar-
dial dysfunction detected by STE may provide further 
information about the course of cardiotoxicity. The 
use of a homogeneous outcome definition (LVEF vs 
GLS) and clear cut- off points are warranted when 
confirming the promising results of advanced imaging 
techniques in larger study populations.
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e-figure - A case demonstrating the different imaging parameters after cancer treatment.  
56-year old female patient who was diagnosed with left-sided breast cancer and underwent mastectomy. 
She was treated with a cumulative anthracycline dose of 240 mg/m2 and left sided radiotherapy. Other 
cancer treatment consisted of cyclophosphamide, paclitaxel and Herceptin.       
Panel 1 
Still images of cine loops in the short axis and 4-chamber orientations in diastole (A, B) and systole (C, D) 
show slightly dilated LV at rest and attenuated contraction with enlarged end-systolic volumes. LV 
ejection fraction was 42%, RV ejection fraction was 59%. Late enhancement images (E, F) show prominent 
septal and subtle lateral mid-wall enhancement (arrows). Cine loops in the 4-chamber and short axis can 
be viewed in the supplemental material.  
Panel 2 
Feature-tracking for quantitative assessment of myocardial wall motion. Feature-tracking derived strain 
shows decreased contraction of the anterior wall (arrows in A, B), as well as the septum (arrows in C-F). A 
cine loop of the strain of the cardiac cycle can be viewed in the supplemental material. 
Panel 3 
T1-mapping shows native and post-contrast T1 values as well as ECV values in the normal range, 
demonstrating the complementary value of visual and quantitative assessment of myocardial structure 
and function. 
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